跳至主要内容
临床试验/NCT00161902
NCT00161902已完成3 期

A Randomized, Controlled, Multicenter Study to Evaluate Efficacy and Safety of Fibrin Sealant VH S/D for Hemostasis in Subjects Undergoing Total Hip Replacement

Baxter Healthcare Corporation7 个研究点 分布在 3 个国家开始时间: 2001年8月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
试验地点
7

研究概览

简要总结

The purpose of the study is to monitor the safety of FS VH S/D and evaluate whether FS VH S/D is superior to standard treatment in reducing blood loss in subjects undergoing total hip replacement with cement-free hip prostheses.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Each subject to be included into the study must fulfill the following inclusion criteria:
  • •Subjects receiving a cement free hip prosthesis due to coxarthrosis because of primary or dysplastic arthrosis grade 1 - 3 according to Crowe or rheumatoid arthritis as well as subjects receiving a cement free hip prosthesis due to femur head necrosis (Crowe classification).
  • •ASA and NSAIDs have been discontinued one week prior to surgery
  • •Written informed consent
  • •Male and female at least 19 years of age

排除标准

  • •Subjects fulfilling the following exclusion criteria will not be recruited into the study:
  • •Impaired coagulation
  • •Previous hip surgery
  • •Acetabular roof plastic
  • •Known hypersensitivity to aprotinin or other components of the product
  • •Immunodeficiency
  • •Increased red cell production
  • •Pregnant or lactating women (positive urine or serum pregnancy test; this test is required of any female subject who is not post menopausal or surgically sterilized).
  • •Subjects concurrently participating in another clinical trial or having received another investigational drug within the last 30 days.
  • •Also patients with abnormal coagulation values due to anticoagulants like coumadins or heparin must be excluded.

研究者

申办方类型
Industry

研究点 (7)

Loading locations...

相似试验